Oncoinvent secures new patent expanding protection for Radspherin[®]

China's CNIPA granted the first patent in a new family for Oncoinvent's lead product candidate Radspherin, marking the first worldwide approval in this family and strengthening long-term IP protection. The patent bolsters commercialization and de-risking of the receptor‑independent alpha radiopharmaceutical aimed at eradicating cancer cells in the abdominal cavity after surgery. This is a company‑specific positive development for OSE: ONCIN that could modestly support the share outlook by reducing intellectual property risk.

Analysis

The incremental strengthening of the company’s IP estate in APAC materially changes the commercial negotiation map: expect Chinese and regional partners to pay a premium for exclusive or semi‑exclusive rights (target royalty floors 10–20% and upfronts in the $20–80M range for mid‑stage assets), because a defensible local monopoly reduces launch risk and accelerates local reimbursement discussions. That premium flow will shift value away from later‑stage global acquirers toward regional licensing deals, meaning near‑term upside is more M&A arbitration‑like (licensing headline + regulatory milestones) than pure clinical binary re‑rating. Supply‑chain chokepoints — notably availability of alpha‑emitting isotopes and qualified CDMO capacity in APAC — become the binding constraint: if manufacturing cannot be scaled in 18–36 months, realized margins on any China deal could be cut by 30–50% versus headline royalty math.

Tail risks are concentrated and measurable: (1) narrow claim scope or weak enforceability would collapse partner willingness to pay (timeline: immediate — licensing term sheets will test claim breadth within 3–6 months); (2) adverse clinical or safety data remains the binary downside over 12–36 months; (3) Chinese pricing & compulsory licensing pressure could compress returns by ~40% vs western pricing assumptions over 3–5 years. Reversal triggers include a successful invalidation challenge in China, or discovery of alternate delivery tech that obviates the company’s advantage — both would knock 60–80% off implied licensing value quickly.

Consensus is underestimating two points: first, the asymmetry between headline IP protection and practical enforcement in APAC — legal victory does not guarantee commercial exclusivity; second, the market underprices the operational capex and time needed to secure alpha‑emitter supply and CMC validation in China, which converts IP value into cash much more slowly. That makes a staged, catalyst‑driven exposure preferable to a binary all‑in equity bet: monetize near term via licensing milestones or structured option-like positions while funding downside protection tied to clinical readouts and supply‑chain milestones.

Key Decisions for Investors

• Initiate a 2% NAV long in ONCIN (OSE: ONCIN) with a 12–24 month horizon; hedge by buying a 9–12 month protective put (~30% OTM) to cap downside from clinical/regulatory shocks. Risk/Reward: asymmetric — expect 2–3x upside if one APAC licensing deal is signed (upfront + milestones) vs ~60% downside if clinical or enforceability events occur.
• Construct a long‑dated call spread to capture licensing rerate while limiting premium decay: buy Jan‑2028 calls and sell a higher strike Jan‑2028 call (size 1% NAV net debit). Timeframe/Catalysts: licensing discussions and supply‑chain MoUs within 6–18 months. Risk/Reward: capped loss = premium paid, potential 3:1 upside if deal headlines arrive.
• Relative value pair: long ONCIN (1% NAV) / short PNT (Point Biopharma, 1% NAV) for 12–36 months to isolate company‑specific IP and commercialization upside from broader radiopharma beta. Rationale: isolates licensing and enforcement upside; risk is sector‑wide derating which would hurt both legs — size small and monitor sector flows closely.